Snyder's owns and operates 81 corporate stores and supports more than 100 independent retailers in Iowa, Illinois, Michigan, Minnesota, Montana, South Dakota and Wisconsin under the Snyder's name through its distribution center in Eagan, MN. Drug Emporium owns and operates 77 stores under the names Drug Emporium, F&M Super Drug Stores and Vix Drug Stores. The company also franchises additional stores under the Drug Emporium name.

Snyder's plans to pay $21 million in cash and assume certain liabilities. Under the plan, no distribution will be made to current shareholders of Powell, OH-based Drug Emporium, and all of its existing shares will be canceled.

The plan will go into effect upon the completion of the documentation required by the plan and the closing of a $160-million revolving loan facility and a $40-million term loan facility. Snyder's and Drug Emporium have received commitments for both. The money will be used to get Drug Emporium through the reorganization process and provide working capital for both Drug Emporium and Snyder's.

In addition, a major supplier of pharmaceutical goods to both companies has agreed to provide $40 million in credit enhancements to the new loan facilities as well as enter into a long-term supply agreement with the new combined company.

Snyder's will operate Drug Emporium as a separate wholly-owned subsidiary. The transaction is expected to close in September.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM Digital Member, you’ll receive:

  • Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.